Grant of Stock Acquisition Rights to Directors, Employees, and Others
First written in FY2019-Q2. 6 of 9 entries say "Advanced", first in FY2020. Latest entry: FY2025-H1.
106 other companies' latest entry also says "Advanced".
- FY2025-H1AdvancedAnnual report
「Number of stock acquisition rights (rights)* 23,980 Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 2,398,000 Amount payable upon exercise of stock acquisition rights (¥)* 3,436 Exercise period for stock acquisition rights* From 1 April 2027 To 31 October 2033」
The stock acquisition rights covered by the resolution passed on 29 January 2025 were issued on 21 March 2025, comprising 23,980 rights covering 2,398,000 shares, at an exercise price of ¥3,436, with an exercise period from 1 April 2027 to 31 October 2033. - FY2024AdvancedAnnual report
「Number of stock acquisition rights (rights)* 26,000 Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 2,600,000 Exercise period for stock acquisition rights* From 1 April 2027 To 31 October 2033」
The disclosure specified 26,000 new stock acquisition rights for directors and employees of the Company and its subsidiaries under the resolution passed at the ordinary general meeting of shareholders on 29 January 2025, covering 2,600,000 shares, with an exercise period from April 2027 to October 2033. - FY2023RestatedAnnual report
「For the 2023 stock acquisition rights, the outstanding balance was 2,120,800 shares, and the exercise period runs from 1 April 2025 to 31 October 2031.」
The issue details and outstanding balance of the 2023 stock acquisition rights, together with the exercise period from 2025 to 2031, have been confirmed in the annual disclosure. - FY2023-Q2AdvancedAnnual report
「Category and number of eligible persons (people) Directors of the Company 6 Employees of the Company 532 Directors of the Company's subsidiaries 23 Employees of the Company's subsidiaries 539 Number of stock acquisition rights (rights)* 21,894 Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 2,189,400 Amount payable upon exercise of stock acquisition rights (¥)* 3,525 Exercise period for stock acquisition rights* From 1 April 2025 To 31 October 2031」
The stock acquisition rights covered by the resolution passed at the ordinary general meeting of shareholders on 27 January 2023 were issued on 20 March 2023. The grant comprised 21,894 rights to directors and employees of the Company and its subsidiaries, covering 2,189,400 shares, at an exercise price of ¥3,525, with an exercise period from 1 April 2025 to 31 October 2031. - FY2021-Q2AdvancedAnnual report
「Number of stock acquisition rights (rights)* 14,954 Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 1,495,400 Amount payable upon exercise of stock acquisition rights (¥)* 2,940 Exercise period for stock acquisition rights* From 1 April 2023 To 31 October 2029」
The stock acquisition rights covered by the resolution passed on 28 January 2021 were issued, comprising 14,954 rights covering 1,495,400 shares, at an exercise price of ¥2,940, with an exercise period from 1 April 2023 to 31 October 2029. The eligible recipients were 7 directors of the Company, 435 employees, 19 directors of subsidiaries and 467 employees of subsidiaries. - FY2021-Q1AdvancedAnnual report
「Directors of the Company 7 people 522 rights Employees of the Company 446 people 7,356 rights Directors of the Company's subsidiaries 19 people 1,390 rights Employees of the Company's subsidiaries 507 people 6,225 rights」
Based on a resolution of the Board of Directors passed on 24 February 2021, the allocation details for the fourth series of stock acquisition rights to directors and employees of the Company and its subsidiaries were specified. The number of stock acquisition rights is capped at 15,550, and the exercise period runs from 1 April 2023 to 31 October 2029. - FY2020AdvancedAnnual report
「For the resolution passed at the ordinary general meeting of shareholders held on 28 January 2021, the number of stock acquisition rights was 15,550, the underlying common shares numbered 1,555,000, and the exercise period was from 1 April 2023 to 31 October 2029.」
A resolution was passed to issue new stock acquisition rights to directors and employees of the Company and its subsidiaries, and the number of underlying shares and exercise period were disclosed. - FY2019RestatedAnnual report
「For the 2019 stock acquisition rights, the outstanding balance was 1,118,500 shares, and the exercise period runs from 1 April 2021 to 31 October 2027.」
The terms, remaining number and exercise period of the 2019 stock acquisition rights granted to directors and employees of the Company and its subsidiaries have been confirmed in the annual disclosure. - FY2019-Q2First statedAnnual report
「Category and number of eligible persons (people) Directors of the Company 7 Employees of the Company 354 Directors of the Company's subsidiaries 19 Employees of the Company's subsidiaries 321 Number of stock acquisition rights (rights)* 11,641 Class, details and number of shares underlying the stock acquisition rights (shares)* Common shares 1,164,100 Amount payable upon exercise of stock acquisition rights (¥)* 3,895 Exercise period for stock acquisition rights* From 1 April 2021 To 31 October 2027」
Based on a resolution passed at the ordinary general meeting of shareholders held on 30 January 2019, stock acquisition rights were issued to directors and employees of the Company and its subsidiaries. The issue comprised 11,641 stock acquisition rights, covering 1,164,100 common shares, at an exercise price of ¥3,895 per share, with an exercise period from 1 April 2021 to 31 October 2027. The issue date of the stock acquisition right certificates is stated as 25 March 2019.